Referencias
- Costa RF. Desenvolvimento de métodos de purificação de Gálio-67 e Gálio-68 para marcação de biomolécula. 2012. 149 p. Dissertação (Doutorado em Ciências na Área de Tecnologia Nuclear - Aplicações) – IPEN – Autarquia associada à Universidade de São Paulo. São Paulo, 2012.
- Vallabhajosula S. Molecular imaging: radiopharmaceuticals for PET and SPECT. Berlin Heidelberg: Springer; 2009. 371p.
- Maecke HR, Hofmann M, Haberkorn U. 68Ga-Labeled Peptides in Tumor Imaging. J Nucl Med 2005;46:172S-178S.
- Pagou M, Zerizer I, Al- Nahhas A. Can gallium-68 compounds partly replace 18F-FDG in PET molecular imaging? Hellenic Journal of Nuclear Medicine 2009;12:102-5.
- Decristoforo C, Pickett RD, Verbruggen A. Feasibility and availability of 68Ga-labelled peptides. Eur J Nucl Med Mol Imaging 2012;39:S31-S40.
- Koukouraki S, Strauss LG, Georgoulias V et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-22.
- Ambrosini V, Tomassetti P, Castellucci P et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-8.
- Sowa-Staszkzac A, Pach D, Chrzan R. et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging 2011;38:1669-74.
- Gabriel M, Decristóforo C, Kendler D et al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J Nucl Med 2007;48:508-18.
- Reubi JC. Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy. Endocrine Reviews 2003;24:389-427.
- Kayani I, Bomanji JB, Groves A et al. Functional Imaging of Neuroendocrine Tumors With Combined PET/CT Using 68Ga-DOTATATE (Dota-DPhe1,Tyr3-octreotate) and 18F-FDG. American Cancer Society 2008;112:2447-55.
- Filice A. Radiolabeled SomatostatinAnalogues Therapy inAdvanced Neuroendocrine Tumors: A Single Centre Experience. J Oncol 2012;2012:10 p.
- Ambrosini V, Campana D, Nanni C et al. Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Eur J Nucl Med Mol Imaging 2012;39:1278-83.
- Prasad V, Fetscher S, Baum, RP. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine’s view. J Pharm Pharmaceut Sci 2007;10:321s-337s.
- Srirajaskanthan R, Kayani I, Quigley AM et al. The Role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-Octreotide scintigraphy. J Nucl Med 2010;51:875-82.
- Czepczyński R, Parisella MG, Kosowics J et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1635-45.
- Melero, LTUH. Preparação e padronização de metodologia de marcação “in Vitro” e estudo de biodistribuição do octreotídeo-[tyr3]-Hynic/edda/tricina- [99mtc]. 2008. 136 p. Dissertação (Mestrado em Ciências na Área de Tecnologia Nuclear - Aplicações) – IPEN – Autarquia associada à Universidade de São Paulo. São Paulo, 2008.
- Naswa N, Bal CS. Divergent Role of 68Ga-Labeled Somatostatin Analogs in the Workup of Patients with NETs: AIIMS Experience. In: BAUM, Richard P. (Ed.); ROSCH, Frank (Ed.). Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment. Berlin: Springer, 2013. p. 321-351.
- Hofman MS, Kong G, Neels OC et al. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imag Rad Oncol 2012;56:40-7.
- Velikyan I, Beyer GJ, Bergström-Pettermann E et al. The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. Nucl Med Biol 2008;35:529-36.
- Breeman WAP, Blois E, Chan HS et al. 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;4:314-21.
- Virgolini, I, Ambrosini V, Bomanji JB et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-10.
- Velikyan I. The Diversity of 68Ga-Based Imaging Agents. In: Baum R, Rosch F (Eds.). Theranostics, Gallium-68, and other radionuclides: A pathway to personalized diagnosis and treatment. Berlin: Springer, 2013. p. 101-131.
- Le VS. 68Ga Generator Integrated System: Elution–Purification–Concentration–Integration. In: Baum R, Rosch F (Eds.). Theranostics, Gallium-68, and other radionuclides: A pathway to personalized diagnosis and treatment. Berlin: Springer, 2013. p. 43-73.
- Mueller D, Klette I, Baum RP. Purification and Labeling Strategies for 68Ga from 68Ge/68Ga Generator Eluate. In: Baum R, Rosch F (Eds.). Theranostics, Gallium-68, and other radionuclides: A pathway to personalized diagnosis and treatment. Berlin: Springer, 2013. p. 77-88.
- Buchmann I, Henze M, Engelbrecht S et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
- Kabasakal L, Demirci E, Ocak M et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271-7.
- Fani M, Pozzo LD, Abiraj K et al. PET of Somatostatin receptor–positive tumors using 64Cu- and 68Ga-somatostatin antagonists: The chelate makes the difference. J Nucl Med 2011;52:1110-8.
- Haug AR, Cindea-Drimus R, Auernhammer CJ et al. The Role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012;53:1686-92.
- Haug AR, Auernhammer CJ, Wangler B et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor–mediated radionuclidetTherapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51:1349-56.
- Petinatto C, Sarnelli A, Donna MD et al. 68Ga DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;51:72-9.
- Fanti S, Ambrosini V, Tomassetti P et al. Evaluation of unusual neuroendocrine tumors by means of 68Ga-DOTA-NOC PET. Biomedicine & Pharmacotherapy 2008;62:667-71.
- Ambrosini V, Campana D, Bodei L et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73.
- Campana D, Ambrosini V, Raffaele P et al. Standardized uptake values of 68Ga DOTANOC PET: A promissing prognostic tool in neuroendocrine tumors J Nucl Med 2010;51:353-9.
- Poeppel TD, Binse I, Petersenn S et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864-70.
- Gabriel M, Oberauer A, Dobrozemsky G et al. 68Ga-DOTA-Tyr3-Octreotide PET for assessing response to somatostatin – receptor - mediated radionuclide therapy. J Nucl Med 2009;50:1427-34.
- Velikyan I, Sundin A, Eriksson B et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass. Nucl Medicine Biology 2012;37: 265-75.
- Ruf J, Heuck F, Schiefer J et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. J Neuroendocrinol 2010;91:101-9.
- Froeling V, Elgeti F, Maurer MH et al. Impact of 68Ga DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 2012;26:738-43.
- Kumar R, Sharma P, Garga P et al. Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 2011;21:2408-16.
- Wild D, Bomanji JB, Benkert P et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:1-9.
- Lapinska G, Bryszewska M, Fijołek-Warszewska A et al. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Review 2011;1:16-20.